### PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY	PCT			
To: ERIC POTTER CLARKSON Attn. Pilkington, Stephanie Park View House 58 The Ropewalk	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION			
Nottingham NG1 5DD UNITED KINGDOM  2 8 APR 200	(PCT Rule 44.1)			
Z O AFR ZOU!	Date of mailing (day/month/year) 28/04/2005			
Applicant's or agent's file reference	EGELECTION CONTRACTION			
DUNY/P30950PC	FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No.	International filing date (day/month/year)			
PCT/GB2004/003096	16/07/2004			
Applicant				
UNIVERSITY OF DUNDEE				
UNIVERSITY OF BONDER				
1. X  The applicant is hereby notified that the international search Authority have been established and are transmitted herew Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the clair	•			
When? The time limit for filing such amendments is not International Search Report; however, for more	mally 2 months from the date of transmittal of the details, see the notes on the accompanying sheet.			
Where? Directly to the International Bureau of WIPO, 3-1211 Geneva 20, Switzerland, F	ascimile No.: (41-22) 740.14.35			
For more detailed instructions, see the notes on the according				
Article 17(2)(a) to that effect and the written opinion of the I	n report will be established and that the declaration under nternational Searching Authority are transmitted herewith.			
3. With regard to the protest against payment of (an) additi	onal fee(s) under Rule 40.2, the applicant is notified that:			
applicant's request to forward the texts of both the pro	en transmitted to the International Bureau together with the otest and the decision thereon to the designated Offices.			
no decision has been made yet on the protest; the ap	plicant will be notified as soon as a decision is made.			
4. Reminders  Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.				
The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.				
Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.				
In respect of other designated Offices, the time limit of 30 month months.	s (or later) will apply even if no demand is filed within 19			
See the Annex to Form PCT/IB/301 and, for details about the ap Guide, Volume II, National Chapters and the WIPO Internet site	plicable time limits, Office by Office, see the PCT Applicant's			
Name and mailing address of the International Searching Authority	Authorized officer			

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Geertruida Groeneveld-Van der Spek

#### NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the *PCT Applicant's Guide*, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report and the written opinion of the International Searching Authority, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only (see *PCT Applicant's Guide*, Annexes B1 and B2).

The attention of the applicant is drawn to the fact that amendments to the claims under Article 19 are not allowed where the International Searching Authority has declared, under Article 17(2), that no international search report would be established (see *PCT Applicant's Guide*, Volume I/A, paragraph 296).

### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the international Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

### What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

# PATENT COOPERATION TREATY

# PCT

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220
DUNY/P30950PC	ACTION as we	Il as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/GB2004/003096	16/07/2004	17/07/2003
Applicant	·	
UNIVERSITY OF DUNDEE		
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Aut ansmitted to the International Bureau.	hority and is transmitted to the applicant
This International Search Report consists	of a total of sheets.	•
	a copy of each prior art document cited in this	s report.
Basis of the report     a. With regard to the language, the language in which it was filed, unline.	international search was carried out on the ba ess otherwise indicated under this item.	sis of the international application in the
1	search was carried out on the basis of a trans	lation of the international application furnished to
b. X With regard to any nucleo	otide and/or amino acid sequence disclosed	d in the international application, see Box No. I.
2. Certain claims were fou	nd unsearchable (See Box II).	
3. Unity of invention is lac	king (see Box III).	
4. With regard to the title,		
	ibmitted by the applicant.	
I <u></u>	shed by this Authority to read as follows:	
METHODS FOR USE OF AN	LKB1/STRAD7MO25 COMPLEX	
5. With regard to the abstract,	•	
	ubmitted by the applicant.	5 N N/T
the text has been establis may, within one month fro	shed, according to Rule 38.2(b), by this Author om the date of mailing of this international sea	rity as it appears in Box No. IV. The applicant rch report, submit comments to this Authority.
6. With regard to the drawings,		•
· 1	published with the abstract is Figure No2	<u>1b</u>
X as suggested by	•	
	is Authority, because the applicant failed to su	iggest a figure.
l <u>L.</u>	is Authority, because this figure better charact	
b. none of the figures is to be	be published with the abstract.	

International application No.

PCT/GB2004/003096

Вох	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item	1.b of the first sheet)
1.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international ntion, the international search was carried out on the basis of:	application and necessary to the claimed
	a.	type of material	
		X a sequence listing	•
		table(s) related to the sequence listing	
	b.	format of material	
	D.	X in written format	
		X in computer readable form	
		in computer readable form	
	c.	time of filing/furnishing	
,		contained in the international application as filed	•
		filed together with the international application in computer readable form	<i>r</i>
		X furnished subsequently to this Authority for the purpose of search	
_		In addition, in the case that more than one version or copy of a sequence listing	and/or table relating thereto has been filed
2.	Ш	or furnished, the required statements that the information in the subsequent or application as filed or does not go beyond the application as filed, as appropriate	aditional copies is identical to that in the
		application as these of cores was go any	
3.	Addi	litional comments:	
J.	7100.		
		•	•
		,	
			·
			•
		•	•
			•
		•	
			•

International Application No PCT/GB2004/003096

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/82 C12N9/12

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07 K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUME	NTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	HAWLEY S A ET AL: "Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase."  THE JOURNAL OF BIOLOGICAL CHEMISTRY. 1 NOV 1996, vol. 271, no. 44, 1 November 1996 (1996-11-01), pages 27879-27887, XP002315194 ISSN: 0021-9258 the whole document	1-7, 11-19, 22,23, 30,32, 33,37-39
•	-/	
	ner documents are listed in the continuation of box C. X Patent family members are list	ted in annex.

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
"Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s)-or which is cited to establish the publication date of another	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention
citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search - 28 January 2005	Date of mailing of the international search report 2 8. 04. 2005
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Smalt, R

International Application No
PCT/GB2004/003096

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 200222 Derwent Publications Ltd., London, GB; Class B04, AN 2002-171818 XP002315199 & WO 02/06520 A1 (CHUGAI RES INST MOLECULAR MEDICINE INC) 24 January 2002 (2002-01-24) the whole document -& WO 02/06520 A1 (CHUGAI RES INST MOLECULAR MEDICINE INC) 24 January 2002 (2002-01-24)	1
X	BAAS A F ET AL: "Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 12, 16 June 2003 (2003-06-16), pages 3062-3072, XP002298130 ISSN: 0261-4189 the whole document	28,29
A .	BOUDEAU J ET AL: "LKB1, a protein kinase regulating cell proliferation and polarity" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 546, no. 1, 3 July 2003 (2003-07-03), pages 159-165, XP004433636 ISSN: 0014-5793 the whole document	
Α	NATH NANDITA ET AL: "Yeast Pak1 kinase associates with and activates Snf1." MOLECULAR AND CELLULAR BIOLOGY. JUN 2003, vol. 23, no. 11, June 2003 (2003-06), pages 3909-3917, XP002315195 ISSN: 0270-7306 the whole document	
Α	BEAULOYE^A^ ^B C ET AL: "Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 505, no. 3, 21 September 2001 (2001-09-21), pages 348-352, XP004309604 ISSN: 0014-5793 the whole document	

International Application No
PCT/GB2004/003096

- 12	POCHMENTS CONCIDENCE TO BE BEI FVANT	PC17GB20047003030			
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category Citation of document, with indication, where appropriate, of the relevant passages . Relevant to claim No.					
P,X	HAWLEY SIMON A ET AL: "Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and M025 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade."  JOURNAL OF BIOLOGY (ONLINE) 2003, vol. 2, no. 4, 24 September 2003 (2003-09-24), page 28, XP002298131  ISSN: 1475-4924 the whole document	1,4-6, 15-23, 28-30, 32,33, 37-39			
P,X	SHAW R J ET AL: "The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 101, no. 10, 9 March 2004 (2004-03-09), pages 3329-3335, XP002298134 ISSN: 0027-8424 the whole document	1,24,25, 28-30, 32,33, 37-39			
E E	WO 2004/113562 A1 (MEDICAL RES COUNCIL [GB]; UNIV COLUMBIA [US]; CARLING DAVID [GB]; WOOD) 29 December 2004 (2004-12-29)	1-3,7,9, 11,12, 14-16, 18,20, 21,23, 32,33			
	the whole document				
T .	BOUDEAU JÉRÔME ET AL: "MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm." THE EMBO JOURNAL. 1 OCT 2003, vol. 22, no. 19, 1 October 2003 (2003-10-01), pages 5102-5114, XP002315196 ISSN: 0261-4189 the whole document				
T .	HONG SEUNG-PYO ET AL: "Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 22 JUL 2003, vol. 100, no. 15, 22 July 2003 (2003-07-22), pages 8839-8843, XP002315197 ISSN: 0027-8424 the whole document				

International Application No PCT/GB2004/003096

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	 1_**
Category "	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	SUTHERLAND CATHERINE M ET AL: "Elmlp is one of three upstream kinases for the Saccharomyces cerevisiae SNF1 complex." CURRENT BIOLOGY: CB. 5 AUG 2003, vol. 13, no. 15, 5 August 2003 (2003-08-05), pages 1299-1305, XP002315198 ISSN: 0960-9822 the whole document	
T	WOODS A ET AL: "LKB1 is the upstream kinase in the AMP-activated protein kinase cascade" CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 13, no. 22, 11 November 2003 (2003-11-11), pages 2004-2008, XP002298132 ISSN: 0960-9822 the whole document	
T .	LIZCANO J M ET AL: "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 23, no. 4, 25 February 2004 (2004-02-25), pages 833-843, XP002298133 ISSN: 0261-4189 the whole document	
Т .	HARDIE D G: "THE AMP-ACTIVATED PROTEIN KINASE PATHWAY - NEW PLAYERS UPSTEAM AND DOWNSTREAM"  JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 117, no. PART 23, 2004, pages 5479-5487, XP008040901  ISSN: 0021-9533 the whole document	

Information on patent family members

International Application No PCT/GB2004/003096

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0206520	A1	24-01-2002	AU	7106701 A	30-01-2002
WO 2004113562	A1	29-12-2004	GB US	2402938 A 2005026233 A1	22-12-2004 03-02-2005

International application No. PCT/GB2004/003096

Box II Observations where certain claims	s were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been est	ablished in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.:     because they relate to subject matter not	required to be searched by this Authority, namely:
Claims Nos.:     because they relate to parts of the Internations an extent that no meaningful Internations.	national Application that do not comply with the prescribed requirements to such al Search can be carried out, specifically:
·	
	are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of inve	ention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found mult	iple inventions in this international application, as follows:
see additional sheet	•
As all required additional search fees w searchable claims.	ere timely paid by the applicant, this International Search Report covers all
	ched without effort justifying an additional fee, this Authority did not invite payment
2. As all searchable claims could be search of any additional fee.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3. As only some of the required additiona covers only those claims for which feet	I search fees were timely paid by the applicant, this International Search Report s were paid, specifically claims Nos.:
	•
·	
4. No required additional search fees we restricted to the invention first mention	re timely paid by the applicant. Consequently, this International Search Report is led in the claims; it is covered by claims Nos.:
	etely, and claims 32 and 33 partially
Remark on Protest	The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.
·	

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

- 1. claims: 1-25,28-30,37-39 completely, and claims 32 and 33 partially
- 1.1. claims: 1-25,30 completely, and claims 31-32 partially

An LKB1 complex comprising STRAD and MO25, preparation thereof, and its use in the identification of modulators of its phosphorylation of AMPK.

1.2. claims: 28,29

Method for identifying patients with PJS or an increased susceptibility thereto by analysing the STRAD and/or MO25 genes for mutations.

1.3. claims: 37-39

AMPK subfamily members with a mutaion replacing Thr172 and nucleic acids encoding them

2. claims: 26,27

Method for identifying binding partners of MO25.

3. claims: 31 completely, and claims 32 and 33 partially

Use of an AMPK subfamily member in the manufacture of a medicament for treating diabetes or obesity.  $\,$ 

4. claims: 34-36

Peptide substrates for LKB1 and antibodies reactive therewith